



2021 American Academy of Neurology (AAN) Annual Meeting (Virtual): Eisai Inc. Sponsored Posters

Please see the listing of Eisai Inc. sponsored posters presented at 2021 AAN Annual Meeting below and refer to the Congress Links section available on our Medical Information website which may include additional information.

PERAMPANEL

1. Husni R, Ngo L, Patten P, et al. Perampanel Monotherapy Beyond Initial Titration to Achieve Seizure Freedom in Patients with Partial-Onset Seizures (POS), with or without Secondarily Generalized Seizures (SGS): Post Hoc Analysis of Phase III Study 342 (FREEDOM). Poster presented at: 73rd American Academy of Neurology (AAN) Annual Meeting; April 17-April 22, 2021; Virtual.
2. Shankar R, Salpekar J, Patten A, Malhotra M, Ngo LY. Long-term Evaluation of Adjunctive Perampanel on Mental Health in Pediatric Patients with Partial-Onset Seizures (POS) or Primary Generalized Tonic-Clonic Seizures (PGTCS) in Study 311. Poster presented at: 73rd American Academy of Neurology (AAN) Annual Meeting; April 17-April 22, 2021; Virtual.
3. Flamini R, Patten A, Malhotra M, Ngo L. Long-Term (1-Year) Seizure Freedom with Adjunctive Perampanel in Pediatric Patients (Aged 4–<12 Years) with Partial-Onset Seizures (POS) or Primary Generalized Tonic-Clonic Seizures (PGTCS): Post Hoc Analysis of Study 311. Poster presented at: 73rd American Academy of Neurology (AAN) Annual Meeting; April 17-April 22, 2021; Virtual.
4. Wechsler RT, Wheless J, Resnick T, Salah A, Patten A, Malhotra M. PROVE Study 506: Analysis of a Retrospective, Phase IV Study of Perampanel in Real-World Clinical Care of Patients Based on Study Site Participation in Previous Clinical Trials. Poster presented at: 73rd American Academy of Neurology (AAN) Annual Meeting; April 17-April 22, 2021; Virtual.
5. Brandt C, Renfroe J, Ngo LY, Patten A, Malhotra M. Efficacy and Safety of Adjunctive Perampanel for Myoclonic and Absence Seizures: Post Hoc Pooled Analysis of Adult, Adolescent, and Pediatric Patients in Studies 332, 311, and 232. Poster presented at: 73rd American Academy of Neurology (AAN) Annual Meeting; April 17-April 22, 2021; Virtual.
6. Gil-Nagel A, Wheless J, Kim JH, Wechsler RT, Yamamoto T. Perampanel Monotherapy for the Treatment of Epilepsy: Evidence from a Clinical Trial (Study 342) and Real-World Use (Studies 504 and 506). Poster presented at: 73rd American Academy of Neurology (AAN) Annual Meeting; April 17-April 22, 2021; Virtual.

7. Seo DW, Lee JW, Dash A, Lee SK, Lee SA, Malhotra M. Efficacy and Safety of Low- and High-Dose Perampanel as First Adjunctive Therapy in Patients with Partial-Onset Seizures With or Without Secondarily Generalized Seizures: Post Hoc Analysis of the FAME Study. Poster presented at: 73rd American Academy of Neurology (AAN) Annual Meeting; April 17-April 22, 2021; Virtual.
8. Punia V, Klein P, Kumar D, Salah A, Malhotra M. ELEVATE Study 410 initial results: Phase IV study of perampanel as monotherapy or first adjunctive therapy in patients aged ≥ 4 years with partial-onset or primary generalized tonic-clonic seizures. Poster presented at: 73rd American Academy of Neurology (AAN) Annual Meeting; April 17-April 22, 2021; Virtual.
9. Trigg A, Brohan E, Cocks K, et al. Health State Utility Values in Paediatric Subjects with Partial Onset Seizures (POS) or Primary Generalized Tonic Clonic Seizures (PGTCS) receiving Adjunctive Perampanel. Poster presented at: 73rd American Academy of Neurology (AAN) Annual Meeting; April 17-April 22, 2021; Virtual.
10. Santamarina E, Abril-Jaramillo J, Rodriguez-Osorio X, et al. Perampanel as Early Add-on Therapy for Epilepsy Patients with Focal and Generalized Seizures Treated in Clinical Practice. Poster presented at: 73rd American Academy of Neurology (AAN) Annual Meeting; April 17-April 22, 2021; Virtual.
11. Alsaadi T, Toledo M, Loro FA, et al. Perampanel Monotherapy in Epilepsy Patients with Focal and Generalized Seizures: Real-World Experience. Poster presented at: 73rd American Academy of Neurology (AAN) Annual Meeting; April 17-April 22, 2021; Virtual.
12. D'Souza W, Trinkka E, Wu T, et al. Effectiveness and Tolerability of Perampanel in Epilepsy Patients Treated in Routine Clinical Practice: a Global Pooled Analysis Study. Poster presented at: 73rd American Academy of Neurology (AAN) Annual Meeting; April 17-April 22, 2021; Virtual.

LORCASERIN

1. Devinsky O, Filippov G, Cheng JY, et al. MOMENTUM (Study 304; NCT04572243): A Multicenter, Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of Adjunctive Lorcaserin in Patients with Dravet Syndrome. Poster presented at: 73rd American Academy of Neurology (AAN) Annual Meeting; April 17-April 22, 2021; Virtual.

LEMBOREXANT

1. Jain R, Chepke C, Pinner K, et al. Effect of Lemborexant on Fatigue Severity and Sleep Outcomes Over 12 Months in Subjects With Clinically Significant Fatigue at Baseline. Poster presented at: 73rd American Academy of Neurology (AAN) Annual Meeting; April 17-April 22, 2021; Virtual.
2. Chepke C, Jain R, Pinner K, et al. Effect of Lemborexant on Patient-Reported Distress About Sleeping and Interference with Daily Functioning in Subjects with Insomnia. Poster presented at: 73rd American Academy of Neurology (AAN) Annual Meeting; April 17-April 22, 2021; Virtual.
3. Zammit G, Yardley J, Malhotra M, Pinner K, Moline M. Responder Profiles Over 12 Months for Sleep Onset and Sleep Maintenance Outcomes with Lemborexant. Poster presented at: 73rd American Academy of Neurology (AAN) Annual Meeting; April 17-April 22, 2021; Virtual.
4. Rosenberg R, Kumar D, Perdomo C, Moline M, Malhotra M. Evaluation of Next-Dose Transition from Zolpidem to Lemborexant for the Treatment of Insomnia: A Multicenter Open-label Pilot Study. Poster presented at: 73rd American Academy of Neurology (AAN) Annual Meeting; April 17-April 22, 2021; Virtual.
5. O'Leary B, McElroy H, Adena M, et al. Insomnia treatments and on-the-road driving performance: a systematic literature review. Poster presented at: 73rd American Academy of Neurology (AAN) Annual Meeting; April 17-April 22, 2021; Virtual.

ALZHEIMER'S DISEASE

1. Lynch SY, Irizarry M, Dhadda S, et al. Baseline Characteristics for Clarity AD: A Phase 3 Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study Evaluating lecanemab (BAN2401) in Early Alzheimer's Disease. Poster presented at: 73rd American Academy of Neurology (AAN) Annual Meeting; April 17-April 22, 2021; Virtual.

IMPORTANT INFORMATION - PLEASE READ:

If you would like a full copy of the poster(s) listed above, please submit your request via www.eisaimedicalinformation.com/neurology/medicalinquiry or the Submit a Medical Inquiry Form available on our Medical Information website. Please include specific details: Product(s), Poster Number(s), Author(s), Title(s). You may also email your request to Eisai's Medical Information department at esi_medinfo@eisai.com or call 1-888-274-2378.